Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

Published:2010-07 Issue: Volume: Page:147
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Field

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa;Journal of the European Academy of Dermatology and Venereology;2024-07

2. Carbon 14 and stable isotope synthesis of two potent and selective phosphodiesterase type 4 inhibitors;Journal of Labelled Compounds and Radiopharmaceuticals;2023-07-24

3. Development and optimization of RofA-PAMAM dendrimer complex materials for sustained drug delivery;Materials Today Communications;2022-12

4. CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice;Frontiers in Pharmacology;2019-11-12

5. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases;Journal of Medicinal Chemistry;2017-12-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP